SMA Identified program offers genetic testing for SMA at no charge to individuals in the U.S. CAMBRIDGE, Mass. and SAN FRANCISCO, Aug. 20, 2019 (GLOBE NEWSWIRE) — Biogen Inc. (BIIB) and Invitae Corporation (NVTA) today announced that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy (SMA), will be offered at no charge to individuals in the U.S. as part of the SMA Identified program. The SMA STAT test reduces the time needed for genetic testing to help confirm a definitive diagnosis of SMA from 21 to four days, enabling individuals and physicians to plan and begin treatment earlier for what is often a life-threatening disease.

source https://finance.yahoo.com/news/biogen-invitae-announce-availability-rapid-113000494.html?.tsrc=rss